BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012;27:1850-1857. [PMID: 23020312 DOI: 10.1111/j.1440-1746.2012.07276.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Feng M, Tang C, Feng W, Bao Y, Zheng Y, Shen J. Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy. Onco Targets Ther. 2017;10:3001-3005. [PMID: 28652782 DOI: 10.2147/ott.s136806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Yamasaki T, Saeki I, Sakaida I. Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments. Hepatol Int. 2014;8 Suppl 2:492-498. [PMID: 26201330 DOI: 10.1007/s12072-013-9515-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
4 Liu TH, Hsu CH, Shao YY. Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. Liver Cancer 2018;7:205-8. [PMID: 29888209 DOI: 10.1159/000486763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
5 Park SI, Lee SJ, Lee M, Lee MS, Kim GM, Kim MD, Won JY, Lee DY. Prospective randomized trial comparing pushable coil and detachable coil during percutaneous implantation of port-catheter system for hepatic artery infusion chemotherapy. Abdom Imaging 2015;40:595-600. [PMID: 25214068 DOI: 10.1007/s00261-014-0239-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. J Dig Dis. 2015;16:505-512. [PMID: 26121102 DOI: 10.1111/1751-2980.12267] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
7 Miyaki D, Aikata H, Kan H, Fujino H, Urabe A, Masaki K, Fukuhara T, Kobayashi T, Naeshiro N, Nakahara T. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol. 2013;28:1834-1841. [PMID: 23808713 DOI: 10.1111/jgh.12311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
8 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res 2018;48:E87-97. [PMID: 28656680 DOI: 10.1111/hepr.12932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. BMC Cancer 2013;13:363. [PMID: 23895220 DOI: 10.1186/1471-2407-13-363] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
10 Yan Y, Li J, Han J, Hou N, Song Y, Dong L. Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. Anticancer Drugs 2015;26:540-6. [PMID: 25714249 DOI: 10.1097/CAD.0000000000000218] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
11 Kuruvilla SP, Tiruchinapally G, ElAzzouny M, ElSayed ME. N-Acetylgalactosamine-Targeted Delivery of Dendrimer-Doxorubicin Conjugates Influences Doxorubicin Cytotoxicity and Metabolic Profile in Hepatic Cancer Cells. Adv Healthc Mater 2017;6. [PMID: 28085993 DOI: 10.1002/adhm.201601046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
12 Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:655-62. [PMID: 26137283 DOI: 10.3892/mco.2015.523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
14 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T, Takami T, Yamamoto N. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015;10:e0126649. [PMID: 25992784 DOI: 10.1371/journal.pone.0126649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ahn YE, Suh SJ, Yim HJ, Seo YS, Yoon EL, Kim TH, Lee YS, Yim SY, Kim HR, Kang SH, Jung YK, Kim JH, Yeon JE, Um SH, Byun KS. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut Liver. 2021;15:284-294. [PMID: 32307975 DOI: 10.5009/gnl19367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res 2015;45:755-63. [PMID: 25196816 DOI: 10.1111/hepr.12417] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
18 Chen KT, Tsai KF, Leung HWC, Chan ALF, Wang SY, Liang HL, Tang SY, Chou CK, Chen HY, Chan SH, Li MF. Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience. Medicina (Kaunas) 2021;57:779. [PMID: 34440985 DOI: 10.3390/medicina57080779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol 2019;17:143. [PMID: 31416447 DOI: 10.1186/s12957-019-1685-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS One 2019;14:e0218136. [PMID: 31194789 DOI: 10.1371/journal.pone.0218136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer 2018;18:633. [PMID: 29866075 DOI: 10.1186/s12885-018-4519-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
22 Nemoto T, Matsuda H, Nosaka T, Saito Y, Ozaki Y, Hayama R, Naito T, Takahashi K, Ofuji K, Ohtani M, Hiramatsu K, Suto H, Nakamoto Y. Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Mol Clin Oncol 2014;2:1028-34. [PMID: 25279193 DOI: 10.3892/mco.2014.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. J Gastrointest Oncol. 2018;9:741-749. [PMID: 30151271 DOI: 10.21037/jgo.2018.05.13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Obi S, Sato S, Kawai T. Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer. 2015;4:188-199. [PMID: 26674592 DOI: 10.1159/000367746] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
25 Moriya K, Namisaki T, Sato S, Furukawa M, Douhara A, Kawaratani H, Kaji K, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Yoshiji H. Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. Clin Mol Hepatol. 2019;25:381-389. [PMID: 31405269 DOI: 10.3350/cmh.2019.0037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
26 Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. J Gastroenterol Hepatol 2015;30:726-32. [PMID: 25311578 DOI: 10.1111/jgh.12821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol. 2018;33:1780-1786. [PMID: 29645345 DOI: 10.1111/jgh.14152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
28 Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Sci. 2016;107:1263-1269. [PMID: 27315783 DOI: 10.1111/cas.12992] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
29 Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-chayama H, Kawakami Y, Ochi H, Chayama K. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol 2018;53:107-18. [DOI: 10.1007/s00535-017-1348-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kuruvilla SP, Tiruchinapally G, Crouch AC, ElSayed MEH, Greve JM. Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. PLoS One 2017;12:e0181944. [PMID: 28829785 DOI: 10.1371/journal.pone.0181944] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
31 Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita YI, Chikamoto A, Baba H. Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. Surg Case Rep 2018;4:102. [PMID: 30159613 DOI: 10.1186/s40792-018-0510-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Chayama K. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib: Sorafenib for HCC with extrahepatic metastasis. Hepatol Res 2014;44:1320-8. [DOI: 10.1111/hepr.12307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
33 Liu Y, Bi T, Dai W, Wang G, Qian L, Gao Q, Shen G. Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. Tumour Biol 2016;37:7589-97. [PMID: 26687645 DOI: 10.1007/s13277-015-4642-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
34 Wei LY, Zhai YZ, Feng GH. Serum prealbumin combined with Child-Pugh classification and MELD score for evaluation of liver function in patients with liver cirrhosis. Shijie Huaren Xiaohua Zazhi 2014; 22(13): 1871-1875 [DOI: 10.11569/wcjd.v22.i13.1871] [Reference Citation Analysis]
35 Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res 2018;48:1118-30. [PMID: 30030881 DOI: 10.1111/hepr.13232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]